A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists.

Trial Profile

A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Acronyms EXTRA
  • Sponsors Genentech
  • Most Recent Events

    • 24 May 2017 Results of pooled analysis of 2 randomised trials (n=1090, EXTRA and INNOVATE) presented at the 113th International Conference of the American Thoracic Society
    • 07 Mar 2016 Results of a post-hoc analysis assessing biomarkers presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 12 Oct 2011 Actual end date (November 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top